Abstract
Background: Psoriasis is prevalent in ∼1% of children and adolescents in the general population. Current treatment options are few, including mostly off-label systemic therapies and limited use of currently approved biologics for pediatric psoriasis, resulting in a high-unmet medical need. Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has demonstrated sustained long-term efficacy with a favorable safety profile in various psoriatic disease manifestations in adults.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
